Cytodyn Inc (CYDY)

[kgromax]

Upon the interim review of Cytodyn’s pending COVID trial, its Data Safety Monitoring Committee (the only ones having access to unblinded trial data) have made a request for a new, unplanned, interim review at 75%. This demand was backed with 3 words, according to CEO Nader Pourhassan (Oct. 20th conf call):

“Sample Size Reassessment”

Sample = The trial patients
Size = The number of these patients
Reassessment = evaluating if there are enough for the trial to have any chance to detect the hypothetical Leronlimab effect

The company has rejected this demand.

Today we still don’t have any press release from the company about this trial, despite completion. We know the CEO has been VERY aggressive with press releases in the past.
In parallel the company has paid for a new Proactive post, published yesterday, that talks about long haulers, NASH, cancer, etc...
Merry go round.
Writing is on the wall.